Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Is early in the p53 race and Kevetrin is suited up though in need of a new Uni (oral formulation)

Which drug / company is “the one” to finish first - tbd

Remember reading this article, below, with the conclusion painting the picture of what things may come... precision (tailored) medicine, which we’re already starting to see the first signs of (targeted gene-based therapy)

From:
“The p53 Circuit Board”
Biochim Biophys Acta. 2012 Apr; 1825(2): 229–244.
Published online 2012 Feb 7. doi: 10.1016/j.bbcan.2012.01.004

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307870/

—

Final Remarks

We ask the reader to picture the following scenario, not too far into the future. During an annual check up, the reader is found to carry a non-resectable tumor. Pathologists report that is a tumor type for which no single agent therapy has proven useful. The pathology report indicates that the tumor is wild type for p53, MDM2 positive, MDM4 negative. The oncologist orders two assays: i) a genome wide shRNA screen for synthetic lethality with an approved MDM2 inhibitor, to be performed on a growing explant derived from a fresh tumor biopsy; and ii) a global RNA and protein profile of gene expression for the tumor tissues and a few select normal tissues. Two weeks later the results arrive as a list of possible synthetic lethal drug combinations and digital blueprints of the p53 circuit boards in the tumor and normal tissues. A week later treatment begins with sequential combinations of an MDM2 inhibitor with other targeted therapies predicted to be synthetic lethal only in tumor cells. All drugs are administered at low doses and for short periods of time. Within days, the tumor regresses and the reader is considered cancer free. Science fiction or rational optimism?